AstraZeneca announced that it will spend around $1.8 billion to acquire the clinical-stage biopharmaceutical company CinCor Pharma Inc., based in the United States, in order to expand its line of heart and kidney medications...
IntoCell, a South Korean biotech that is developing novel antibody drug conjugate (ADC) platform technologies, will provide proprietary drug-linkers developed using their proprietary Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) system and payload...
The Indian pharmaceutical industry was ripe for disruption, & the exigencies built by the covid-19 pandemic provided the e-pharmacy format the highly required push
BioNTech SE announced a partnership with the UK government to enrol up to 10,000 patients in clinical trials for personalised cancer therapies by the end of 2030...
Gobal pharma major Lupin Limited has announced the launch of a novel fixed-dose triple drug combination (FDC) of Indacaterol, Glycopyrronium and Mometasone, under the brand name DIFIZMA in India, for managing inadequately controlled asthma among...
Aurobindo Pharma on said its wholly-owned subsidiary Eugia Pharma Specialities received final approval from the US Food and Drug Administration (US FDA) to manufacture and market Azacitidine for injection 100 mg single-dose vial....
Geron Corp's shares rose 50% after the company announced that its experimental blood cancer drug helped more patients achieve blood transfusion independence when compared to a placebo in a late-stage trial. Imetelstat, Geron's lead drug, was being...
Everest Medicines, a biopharmaceutical company, has announced its strategic plans for the next two years and beyond, as the company strives to become a fully-integrated biopharmaceutical company with expertise and capabilities spanning the entire...
Granules India Limited, enters into a strategic partnership with Greenko ZeroC to collaborate for green molecule solutions and its wider applications in pharmaceuticals to build a leadership position in sustainability and circular economy...
BDR Pharmaceutical has launched the first generic Apalutamide (Brand name Apatide) in India to treat metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). ..
, CDSCO.jpg)
